Literature DB >> 31064629

Prevalence of non-tuberculous mycobacteria in HIV-infected patients admitted to hospital with pneumonia.

N C Lapinel1, S E Jolley1, J Ali1, D A Welsh1.   

Abstract

<sec id="st1"> <title>BACKGROUND</title> People living with the human immunodeficiency virus (PLWH) may be particularly vulnerable to the consequences of non-tuberculous mycobacteria (NTM) given their defective T cell-mediated immunity and high rates of structural lung disease. </sec> <sec id="st2"> <title>OBJECTIVE</title> To determine the prevalence of NTM in PLWH hospitalized with pneumonia and to assess the potential predictors of NTM isolation. </sec> <sec id="st3"> <title>METHODS</title> Secondary data analysis of a prospective cohort study (2007-2011) of early bronchoscopy in PLWH presenting with suspected pneumonia was undertaken. Subjects with any species of NTM, henceforth described as 'NTM of undetermined significance' (NTM-US), isolated from sputum or bronchoalveolar lavage fluid (BALF), were included in the analysis. Potential predictors were chosen a priori. </sec> <sec id="st4"> <title>RESULTS</title> Among 196 HIV-infected subjects hospitalized with pneumonia, 96 had respiratory samples positive for NTM-US, with 91% of all NTM-US isolated from sputum compared with BALF. The overall prevalence of NTM-US was 49% (96/196). More NTM subjects were smokers (P = 0.08), with a history of chronic obstructive pulmonary disease (P = 0.08). Among those with pathogenic NTM, 39% (34/88) would have met American Thoracic Society microbiologic criteria for NTM pulmonary disease (17% of total cohort). </sec> <sec id="st5"> <title>CONCLUSIONS</title> Respiratory cultures, predominantly sputum samples, were positive for NTM-US in 45% of HIV-infected subjects admitted to hospital for pneumonia. Further research is needed to characterize the prevalence of NTM in PLWH and help establish specific diagnostic criteria in this population. </sec>.

Entities:  

Mesh:

Year:  2019        PMID: 31064629      PMCID: PMC6855835          DOI: 10.5588/ijtld.18.0336

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  35 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  Non-tuberculous mycobacteria disease as a cause of hospitalization in HIV-infected subjects.

Authors:  Maria Jose Miguez-Burbano; Monica Flores; David Ashkin; Allan Rodriguez; Ana Maria Granada; Noaris Quintero; Arthur Pitchenik
Journal:  Int J Infect Dis       Date:  2005-11-14       Impact factor: 3.623

Review 3.  Epidemiology of disease caused by nontuberculous mycobacteria.

Authors:  C R Horsburgh
Journal:  Semin Respir Infect       Date:  1996-12

4.  The antimicrobial susceptibility of non-tuberculous mycobacteria.

Authors:  S Cowman; K Burns; S Benson; R Wilson; M R Loebinger
Journal:  J Infect       Date:  2015-12-24       Impact factor: 6.072

5.  Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

Authors:  Kenneth N Olivier; David J Weber; Richard J Wallace; Ali R Faiz; Ji-Hyun Lee; Yansheng Zhang; Barbara A Brown-Elliot; Allison Handler; Rebecca W Wilson; Michael S Schechter; Lloyd J Edwards; Subha Chakraborti; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2002-11-14       Impact factor: 21.405

6.  Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers.

Authors:  P T Diaz; M A King; E R Pacht; M D Wewers; J E Gadek; H N Nagaraja; J Drake; T L Clanton
Journal:  Ann Intern Med       Date:  2000-03-07       Impact factor: 25.391

7.  Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends.

Authors:  J A Havlik; C R Horsburgh; B Metchock; P P Williams; S A Fann; S E Thompson
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

8.  Accelerated course of human immunodeficiency virus infection after tuberculosis.

Authors:  C Whalen; C R Horsburgh; D Hom; C Lahart; M Simberkoff; J Ellner
Journal:  Am J Respir Crit Care Med       Date:  1995-01       Impact factor: 21.405

9.  Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus.

Authors:  Theodore K Marras; Alison Morris; Leah C Gonzalez; Charles L Daley
Journal:  Am J Respir Crit Care Med       Date:  2004-06-23       Impact factor: 21.405

10.  Non-tuberculous mycobacteria in the sputum of HIV-infected patients: infection or colonization?

Authors:  G Alvarez-Uria; V Falcó; N Martín-Casabona; M Crespo; S Villar Del Saz; A Curran; I Ocaña; E Ribera; A Pahissa
Journal:  Int J STD AIDS       Date:  2009-03       Impact factor: 1.359

View more
  5 in total

1.  Clinical Characteristics and Mortality of Non-tuberculous Mycobacterial Infection in Immunocompromised vs. Immunocompetent Hosts.

Authors:  Jingjing Chai; Xu Han; Qimin Mei; Tao Liu; Joseph Harold Walline; Jia Xu; Yecheng Liu; Huadong Zhu
Journal:  Front Med (Lausanne)       Date:  2022-05-18

2.  Long-term case-fatality rate of nontuberculous mycobacterial disease in people living with HIV.

Authors:  Jingjing Hu; Ling Gu; Yueming Shao; Renfang Zhang; Tangkai Qi; Jianjun Sun; Zhenyan Wang; Wei Song; Yang Tang; Jiangrong Wang; Shuibao Xu; Junyang Yang; Yinzhong Shen; Li Liu; Jun Chen; Hongzhou Lu
Journal:  Infect Dis Poverty       Date:  2022-02-07       Impact factor: 4.520

Review 3.  Non-tuberculous mycobacteria pulmonary disease: A review of trends, risk factors, diagnosis and management.

Authors:  L Nqwata; A R Ouédrago
Journal:  Afr J Thorac Crit Care Med       Date:  2022-07-15

4.  Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006-2021: a systematic review and meta-analysis.

Authors:  Yunchun Zhou; Wei Mu; Jihua Zhang; Shi Wu Wen; Smita Pakhale
Journal:  BMJ Open       Date:  2022-08-01       Impact factor: 3.006

Review 5.  Protective Efficacy of BCG Vaccine against Mycobacterium leprae and Non-Tuberculous Mycobacterial Infections.

Authors:  Davit Orujyan; William Narinyan; Subhapradha Rangarajan; Patrida Rangchaikul; Chaya Prasad; Beatrice Saviola; Vishwanath Venketaraman
Journal:  Vaccines (Basel)       Date:  2022-03-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.